SCHEMBL25698017

SCHEMBL25698017

O=C(O)c1c(Cl)cc(Cl)nc1N1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 3/20 0.50
FABP4 P15090 3/20 0.50
FABP5 Q01469 3/20 0.50
CYP2C9 P11712 2/20 0.50
ALDH1A1 P00352 3/20 0.48
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CNR2 P34972 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
KMO O15229 2/20 0.39
GLP1R P43220 1/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25697994 0.86 NPSR1 (0.45) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL24070271 0.85 KDM4E (0.41) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL23779523 0.83 FABP3 (0.54) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL25698228 0.81 SPR (0.46) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL24069564 0.81 SPR (0.46) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL24070798 0.81 L3MBTL3 (0.38) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL24070539 0.80 SPR (0.44) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL24070559 0.80 SPR (0.41) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL24070601 0.77 ALDH1A1 (0.36) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL25698253 0.77 FFAR2 (0.34) FABP3FABP4FABP5CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115551867-B Fused tricyclic compounds, pharmaceutical compositions and uses thereof 劲方医药科技(上海)有限公司 2024-02-20 CN disclosed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
CN-115551867-A Fused tricyclic compound, pharmaceutical composition and application thereof 劲方医药科技(上海)有限公司 2022-12-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF KRAS, NRAS, TP53 FABP3 4864/4885FABP4 4823/4885FABP5 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.